Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Wall Street Zen
by Doug Wharley · The Cerbat GemOncolytics Biotech (NASDAQ:ONCY – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a note issued to investors on Saturday.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.
Read Our Latest Research Report on Oncolytics Biotech
Oncolytics Biotech Price Performance
Shares of ONCY opened at $0.96 on Friday. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.51. The company has a market capitalization of $111.52 million, a P/E ratio of -3.31 and a beta of 0.98. The firm’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $1.05.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). On average, equities analysts anticipate that Oncolytics Biotech will post -0.28 earnings per share for the current year.
Insider Buying and Selling at Oncolytics Biotech
In other Oncolytics Biotech news, Director Bernd R. Seizinger purchased 100,000 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were purchased at an average cost of $1.04 per share, with a total value of $104,000.00. Following the completion of the purchase, the director owned 466,991 shares of the company’s stock, valued at $485,670.64. The trade was a 27.25% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Wayne Pisano acquired 30,000 shares of the stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.84 per share, with a total value of $25,200.00. Following the completion of the acquisition, the director owned 492,414 shares in the company, valued at approximately $413,627.76. The trade was a 6.49% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 404,282 shares of company stock valued at $363,232. 0.10% of the stock is owned by insiders.
Institutional Trading of Oncolytics Biotech
Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new stake in Oncolytics Biotech during the third quarter valued at about $535,000. Connective Capital Management LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter worth about $131,000. XTX Topco Ltd bought a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $69,000. Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech in the 4th quarter valued at about $68,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech during the 4th quarter valued at about $63,000. 6.82% of the stock is owned by institutional investors.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.
Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.